Skip to main content
Signal8

Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer

$JAGXPress releaseOct 14, 2026, 9:00 AM ETRead the release

Jaguar Health's subsidiary Napo Pharmaceuticals presented positive preliminary open-label pilot data for crofelemer in adult Type 1 short bowel syndrome patients with intestinal failure at ACG 2026 on October 13. Four of six planned subjects completed the 12-week protocol: two saw ostomy volume fall ~5%, one reduced parenteral support volume by 9%, and three improved urinary output by an average of 88%, sustained four weeks after stopping therapy, with no significant adverse events.

Key figures

Drug Name
crofelemer powder for oral solution
Phase Of Trial
open-label pilot study (Phase 2 RCT ongoing)
Dosing
3 mg/kg/dose orally three times daily for 12 weeks
Subjects planned
6
Subjects completed
4
Ps volume reduction pct
9% in one subject
Ostomy volume reduction pct
5% average decrease at 12 weeks in two subjects
Urinary output improvement pct
88% average improvement in three subjects
Ostomy output rebound post cessation pct
23% average increase in three subjects

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.